Qualifying Leads for Transition to Early Trials

The goal of the drug discovery process is obviously to find molecules that could be suitable for eventual clinical testing. Following definition of an optimized lead structure/ however/ a substantial amount of drug 

Verdine GL. The combinatorial chemistry of nature. Nature 1996 384(suppl) ll-3. 

Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandmg S, Christian M, Arbuck S, Hollingshead M, Sausville EA. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001 84 1424-31. 

Supko JG, Eder JP Jr, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res 2003 9 5178-86. 

McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993 13 7587-95. 

---

This chapter discusses four important considerations in drug discovery definition of drug targets, generating diversity, definition of lead structures, and qualifying leads for transition to early trials. Many of the examples will be drawn from the realm of cancer chemotherapy, but the principles should be broadly applicable to a wide variety of disease types. 

---